Treatment for acute ischemic stroke within 24 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had an acute ischemic stroke within the last 24 hours and have some neurological deficits.
- Your stroke severity must be moderate, scoring between 6 and 25 on the NIHSS scale (used to measure stroke symptoms).
- You must be able to receive the study drug within 24 hours of the stroke onset.
- You must not have received or plan to receive other clot-busting or clot-removal treatments for this stroke.
- You must be willing to use birth control if you are of childbearing potential, or if you have a partner who could become pregnant.
- You must sign a consent form after receiving full information about the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.